Please assess the completion status of the following clinical trial:

Trial Title: To Evaluate the Safety and Tolerability of Combined Administration of SHR2285 Tablets With Aspirin, Clopidogrel or Ticagrelor in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy subjects, aged 18-55 (including boundary);~2. Body mass index (BMI) between 19 to 28 kg/m2 (including boundary), male body weight ≥50 kg and \<90 kg , female body weight ≥45kg and \<90kg;~3. Participant with no clinically significant findings in vital signs, physical examination, 12-lead ECG ,X-ray and laboratory parameters，etc.~4. Understand the study procedures and methods, voluntary to participate in the study and signed the informed consent.~Exclusion Criteria:~1. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or total bilirubin/direct bilirubin \> 1.2 fold ULN during screening/baseline.~2. Serum creatinine\> ULN during screening/baseline.~3. Positive faecal occult blood~4. Abnormal coagulation function.~5. A clinical history of coagulation dysfunction; subjects with adverse reaction of antiplatelet drugs or anticoagulant drugs.~6. Subjects with severe head trauma or head surgery within 2 years or surgery within 3 months prior to the screening.~7. Blood donation or blood loss within 1 month≥200 mLor≥400 mL within 3 months before administration.~8. Human immunodeficiency virus antibody, syphilis serological examination, hepatitis b virus surface antigen, hepatitis c virus antibody were positive.~9. 3 months prior to screening involved in any drug or medical device clinical studies. .~10. Female subjects who did not receive contraception at least 30 days before administration and etc.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- group A： Aspirin + Clopidogrel + placebo or SHR2285 (dose 1) (Type: EXPERIMENTAL): None
- group B ：Aspirin + Clopidogrel + placebo or SHR2285 (dose 2) (Type: EXPERIMENTAL): None
- group C： Aspirin + Ticagrelor + placebo or SHR2285 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).